Impact of Biopsy Attempts, Race, and Access on Time to Initiation of Treatment for Pancreatic Cancer
ConclusionsEUS biopsy significantly impacts time between suspicion and treatment of PDAC. This may be exacerbated by clinical practices increasingly favoring neo-adjuvant therapy that necessitates biopsy-proven disease. Time to treatment may also be impacted by access to tertiary centers and racial disparities.
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Gastroenterology | Insurance | Medicare | Pancreas | Pancreatic Cancer | Surgery | Ultrasound